Click here to read the Cover Story, "Specialists discuss role of biosimilars in future of retinal disease management."
Biosimilars are coming and are here to stay.
The patents for bevacizumab and ranibizumab expired in 2019 and 2020, respectively, in the U.S. and in 2022 in Europe. The aflibercept patent may expire in 2023 in the U.S. and in 2025 in Europe. Thus, numerous biosimilars are expected to gain approval, and it is important that our community becomes educated about the defining features of a biosimilar, the differentiation between biosimilars and generics, the biosimilar manufacturing